Methylation Status of CpG Sites in the MCP-1 Promoter is Correlated to Serum MCP-1 in Type 2 Diabetes

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2011 Oct 7

PMID 21975431

Citations 25

Authors

Z H Liu

L L Chen

X L Deng

H J Song

Y F Liao

T S Zeng

J Zheng

H Q Li

Affiliations

Soon will be listed here.

Abstract

Aim: Monocyte chemoattractant protein-1 (MCP-1) is a potent chemokine and plays an important role in atherosclerosis of Type 2 diabetes. The aim of this study was to investigate the methylation status of CpG sites in the MCP-1 promoter in Type 2 diabetic patients and its correlation to serum MCP- 1 level, and blood glucose level.

Methods: The 32 patients with Type 2 diabetes and 15 healthy controls were enrolled into the study. Bodymass index, blood pressure, blood lipid, blood glucose, glycosylated hemoglobin (HbA1c), and serum MCP-1 were measured. Genomic DNA was isolated fromthe peripheral blood mononuclear cells (PBMC). Methylation status of CpG sites in theMCP-1 promoter was determined using methylation specific polymerase chain reaction.

Results: The promoter region (2890-3050 bp) was predominantly methylated in PBMC from controls.Methylation of CpGmotifs were less methylated in the patients than in the controls (25% vs 80%; p<0.001), while the level of MCP-1 in serum was higher in patients with Type 2 diabetes (193.95±74.96 vs 88.46±55.10; p<0.001). MCP-1 promoter methylation was significantly correlated to serum MCP-1, HbA1c, fasting blood glucose, and triglyceride.

Conclusion: These data suggest that hypomethylation of CpG sites in the MCP-1 promoter region may be affected by blood glucose and TG, which then increase the serum MCP-1 level and may play a role in the vascular complications of Type 2 diabetes.

Citing Articles

Longitudinal cytokine and multi-modal health data of an extremely severe ME/CFS patient with HSD reveals insights into immunopathology, and disease severity.

Jahanbani F, Sing J, Maynard R, Jahanbani S, Dafoe J, Dafoe W Front Immunol. 2024; 15:1369295.

PMID: 38650940 PMC: 11033372. DOI: 10.3389/fimmu.2024.1369295.

Genetics and epigenetics of diabetes and its complications in India.

Priyadarshini A, Madan R, Das S Hum Genet. 2023; 143(1):1-17.

PMID: 37999799 DOI: 10.1007/s00439-023-02616-3.

Comparative Study of the Cytokine Profiles of Serum and Tissues from Patients with the Ossification of the Posterior Longitudinal Ligament.

Fay L, Kuo C, Chang H, Yeh M, Chang C, Ko C Biomedicines. 2023; 11(7).

PMID: 37509659 PMC: 10377187. DOI: 10.3390/biomedicines11072021.

Epigenetic Reprogramming of the Inflammatory Response in Obesity and Type 2 Diabetes.

Zatterale F, Raciti G, Prevenzano I, Leone A, Campitelli M, De Rosa V Biomolecules. 2022; 12(7).

PMID: 35883538 PMC: 9313117. DOI: 10.3390/biom12070982.

Ding Q, Gao Z, Chen K, Zhang Q, Hu S, Zhao L Front Immunol. 2022; 13:883410.

PMID: 35603204 PMC: 9120428. DOI: 10.3389/fimmu.2022.883410.

References

Herder C, Baumert J, Thorand B, Martin S, Lowel H, Kolb H . Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol. 2006; 26(9):2147-52. DOI: 10.1161/01.ATV.0000235691.84430.86. View

Gerszten R, Garcia-Zepeda E, Lim Y, Yoshida M, Ding H, Gimbrone Jr M . MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999; 398(6729):718-23. DOI: 10.1038/19546. View

Nelken N, Coughlin S, Gordon D, Wilcox J . Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991; 88(4):1121-7. PMC: 295565. DOI: 10.1172/JCI115411. View

Davi G, Tuttolomondo A, Santilli F, Basili S, Ferrante E, Di Raimondo D . CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke. J Atheroscler Thromb. 2009; 16(6):707-13. DOI: 10.5551/jat.1537. View

Cooper M, El-Osta A . Epigenetics: mechanisms and implications for diabetic complications. Circ Res. 2010; 107(12):1403-13. DOI: 10.1161/CIRCRESAHA.110.223552. View

Esposito K, Nappo F, Giugliano F, Di Palo C, Ciotola M, Barbieri M . Cytokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care. 2003; 26(5):1647. DOI: 10.2337/diacare.26.5.1647. View

Baccarelli A, Tarantini L, Wright R, Bollati V, Litonjua A, Zanobetti A . Repetitive element DNA methylation and circulating endothelial and inflammation markers in the VA normative aging study. Epigenetics. 2010; 5(3):222-8. PMC: 3155741. DOI: 10.4161/epi.5.3.11377. View

Ng S, Lin R, Laybutt D, Barres R, Owens J, Morris M . Chronic high-fat diet in fathers programs β-cell dysfunction in female rat offspring. Nature. 2010; 467(7318):963-6. DOI: 10.1038/nature09491. View

Hoogeveen R, Morrison A, Boerwinkle E, Miles J, Rhodes C, Sharrett A . Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis. 2005; 183(2):301-7. DOI: 10.1016/j.atherosclerosis.2005.03.007. View

10.

Beckman K, Ames B . The free radical theory of aging matures. Physiol Rev. 1998; 78(2):547-81. DOI: 10.1152/physrev.1998.78.2.547. View

11.

Herder C, Baumert J, Thorand B, Koenig W, de Jager W, Meisinger C . Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002. Diabetologia. 2006; 49(5):921-9. DOI: 10.1007/s00125-006-0190-y. View

12.

Turunen M, Aavik E, Yla-Herttuala S . Epigenetics and atherosclerosis. Biochim Biophys Acta. 2009; 1790(9):886-91. DOI: 10.1016/j.bbagen.2009.02.008. View

13.

Namiki M, Kawashima S, Yamashita T, Ozaki M, Hirase T, Ishida T . Local overexpression of monocyte chemoattractant protein-1 at vessel wall induces infiltration of macrophages and formation of atherosclerotic lesion: synergism with hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2002; 22(1):115-20. DOI: 10.1161/hq0102.102278. View

14.

Simeoni E, Hoffmann M, Winkelmann B, Ruiz J, Fleury S, Boehm B . Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus. Diabetologia. 2004; 47(9):1574-80. DOI: 10.1007/s00125-004-1494-4. View

15.

El-Osta A, Brasacchio D, Yao D, Pocai A, Jones P, Roeder R . Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med. 2008; 205(10):2409-17. PMC: 2556800. DOI: 10.1084/jem.20081188. View

16.

. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997; 20(7):1183-97. DOI: 10.2337/diacare.20.7.1183. View

17.

Yuasa S, Maruyama T, Yamamoto Y, Hirose H, Kawai T, Matsunaga-Irie S . MCP-1 gene A-2518G polymorphism and carotid artery atherosclerosis in patients with type 2 diabetes. Diabetes Res Clin Pract. 2009; 86(3):193-8. DOI: 10.1016/j.diabres.2009.09.001. View

18.

Lim S, Gu J, Kim M, Kim H, Park Y, Park C . Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology. 2008; 135(6):2128-40, 2140.e1-8. DOI: 10.1053/j.gastro.2008.07.027. View

19.

Piemonti L, Calori G, Mercalli A, Lattuada G, Monti P, Garancini M . Fasting plasma leptin, tumor necrosis factor-alpha receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women: impact on cardiovascular mortality. Diabetes Care. 2003; 26(10):2883-9. DOI: 10.2337/diacare.26.10.2883. View

20.

Yu X, Ling W, Mi M . Relationship of impairment induced by intracellular S-adenosylhomocysteine accumulation with DNA methylation in human umbilical vein endothelial cells treated with 3-deazaadenosine. Int J Exp Pathol. 2009; 90(6):638-48. PMC: 2803255. DOI: 10.1111/j.1365-2613.2009.00687.x. View